PMN
ProMIS Neurosciences, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$12.60
−2.33%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | 10.4M | — |
| Gross Profit | — | — | — | (10.4M) | — |
| Operating Expenses | |||||
| R&D Expense | 35.7M | 33.4M | 10.6M | 7.9M | 16.1B |
| SG&A Expense | 7.8M | 6.8M | 6.2M | 6.4M | 7.3B |
| General & Admin Expense | 6.4M | 6.8M | 6.2M | 7.4M | 7.3B |
| Selling & Marketing Expense | — | — | — | (1.0M) | — |
| Other Expenses | — | — | — | (5.8M) | — |
| Total Operating Expenses | 43.4M | 40.2M | 16.8M | 8.5M | 23.4B |
| Cost and Expenses | 43.4M | 40.2M | 16.8M | 18.9M | 23.4B |
| Operating Income (EBIT) | (43.4M) | (40.2M) | (16.8M) | (18.9M) | (23.4B) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | 76.8K | 201.4K | 282.1M |
| Net Interest Income | — | — | (76.8K) | (201.4K) | (282.1M) |
| Other Non-Op Income/Expense | 1.2M | 448.2K | 19.6M | 1.4M | 5.3B |
| Non-Operating Income (excl Interest) | (707.0K) | (448.2K) | (19.7M) | (1.1M) | (5.6B) |
| EBT (Pre-Tax Income) | (42.2M) | (39.7M) | 2.8M | (17.5M) | (18.1B) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (42.2M) | (39.7M) | 2.8M | (17.5M) | (18.1B) |
| Earnings from Cont. Ops | (42.2M) | (39.7M) | 2.8M | (17.5M) | (18.1B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (42.2M) | (39.7M) | 2.8M | (17.5M) | (18.1B) |
| Per Share | |||||
| Basic EPS | ($16.89) | ($22.61) | $2.75 | ($35.50) | ($60.25) |
| Diluted EPS | ($16.89) | ($22.61) | $2.75 | ($35.50) | ($60.25) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 9.1M | 1.8M | 1.0M | 491708 | 300104 |
| Diluted Shares Outstanding | 9.1M | 1.8M | 1.1M | 491708 | 300104 |
| Profitability Metrics | |||||
| EBITDA | (42.7M) | (39.7M) | 2.9M | (17.8M) | (17.8B) |
| D&A | — | — | — | 28.0K | — |
| EBIT | (42.7M) | (39.7M) | 2.9M | (17.8M) | (17.8B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026